Biota Pharmaceuticals (NASDAQ: BOTA), headquartered in Alpharetta, GA, is developing direct acting antiviral drugs for treating respiratory infections in at-risk patients with limited therapeutic options.
With $57.2 million in cash, cash equivalents and short term investments, Biota Pharmaceuticals is well capitalized to run its operations which are guided by an experienced management team.
Biota Pharmaceuticals, Inc. (BOTA) released Q2 2016 financial results for the period ending December 31, 2015.
Management provided an update on the progress of their clinical programs.
We maintain our Buy rating on Biota Pharmaceuticals with a price target of $4.50/share.
